Legend biotech to highlight leadership in car-t cell therapy for patients with multiple myeloma at asco and eha

Somerset, n.j.--(business wire)--legend biotech corporation (nasdaq: legn) (legend biotech), a global leader in cell therapy, announced today that new and updated data from the cartitude clinical development program evaluating carvykti® (ciltacabtagene autoleucel; cilta-cel) for patients with multiple myeloma will be presented at the 2024 american society of clinical oncology (asco) annual meeting and the 2024 european hematology association's (eha) hybrid congress. data from cohort d of the ph.
CAR Ratings Summary
CAR Quant Ranking